MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.
MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass. In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for this revolution in chemicals and biofuels. GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
Elicit Plant is an agro-biotech company specialized in crops’ water resistance and in the development of innovative phytosterol-based solutions.
SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.
Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.
Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.
AAVantgarde Bio is focused on developing innovative gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This technology allows for the delivery of larger genes to both ocular and non-ocular tissues, enhancing the potential for effective treatment in patients. By addressing these challenges, AAVantgarde Bio aims to advance the field of gene therapy and improve outcomes for individuals affected by genetic eye diseases.
Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.
Enthera S.r.l. is a biotechnology company based in Milan, Italy, founded in 2016. The company focuses on developing innovative therapeutic approaches for diabetes and related gastrointestinal complications, particularly enteropathy, along with other intestinal disorders that share similar biological pathways. Enthera operates a monoclonal antibody discovery platform to create first-in-class biologics aimed at addressing these underserved conditions. The company was established as a subsidiary of BiovelocITA S.r.l. and was founded in collaboration with scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio. The name "Enthera" is derived from a combination of the terms "entero," referring to the intestine, and "therapy," reflecting its commitment to developing targeted treatments.
Pixium Vision is a bioelectronics company based in Paris, France, focused on developing retinal implant systems to restore sight for individuals blinded by retinal degenerative diseases. The company is known for its PRIMA System, a bionic vision solution designed to treat blindness caused by the degeneration of photoreceptor cells in the retina. Pixium's initial device, the IRIS1, utilizes an epi-retinal implant and is undergoing clinical trials aimed at obtaining regulatory approval. A second-generation device, IRIS2, is in development, promising enhanced visual acuity through advanced technologies. Additionally, the company is working on IRIS3, a sub-retinal implant that aims to significantly improve vision compared to its predecessors. Established in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with several prestigious institutions, including Stanford University and Moorfields Eye Hospital, and is supported by prominent European venture capital firms.
PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Epsilen Bio Srl, founded in December 2019 and based in Milan, Italy, focuses on developing innovative therapies for patients with underserved medical conditions. The company is dedicated to creating transformative treatments through a process known as epigenetic silencing, which aims to achieve stable genomic silencing of genes implicated in various pathological processes. By targeting these specific genes, Epsilen Bio seeks to address significant unmet medical needs and improve patient outcomes.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Abivax is a clinical-stage biotechnology company based in Paris, France, dedicated to discovering and optimizing treatments for inflammatory diseases, viral infections, and cancer. The company is primarily focused on its lead product, ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s Disease, as well as for COVID-19. Additionally, ABX464 is being evaluated in Phase IIa trials for rheumatoid arthritis and has completed Phase IIa trials aimed at achieving viral remission in HIV patients. Abivax is also developing ABX 196, an immune enhancer in Phase 1/2 trials for hepatocellular cancer, and ABX 544, a candidate for Ebola treatment based on polyclonal antibodies. Furthermore, the company is conducting research into treatments for Dengue fever, influenza, and respiratory syncytial virus. Abivax collaborates with institutions such as the French National Centre for Scientific Research and the University of Montpellier. Founded in 2013, the company aims to harness the body’s immune response to manage chronic inflammatory conditions effectively.
AblaCare is a Paris-based company founded in 2017 that focuses on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed a minimally invasive procedure designed to restore ovulation in patients with PCOS, offering a more natural and less medicalized approach to pregnancy. This innovative treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure can be conducted in a clinic setting, utilizing techniques similar to those used by fertility specialists in in vitro fertilization (IVF). Through its solution, AblaCare aims to enhance the reproductive health and pregnancy experiences of women affected by PCOS.
Microphyt is a company based in Baillargues, France, that specializes in the research, development, production, and marketing of microalgae and other photosynthetic microorganisms. Founded in 2007, Microphyt caters to various markets, including beauty care, food, health, and energy. The company focuses on creating natural algae-based products that support weight loss and promote brain health, while also engaging in industrial farming of microalgae.
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company's lead product candidates include GS010, an AAV2-based gene therapy currently undergoing Phase III clinical trials for treating Leber hereditary optic neuropathy linked to mutations in the ND4 gene, and GS030, which is in Phase I/II trials aimed at addressing retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. In addition to these candidates, GenSight Biologics is advancing other products in preclinical stages targeting various ophthalmic and neurodegenerative conditions. The company was founded in 2012 and remains dedicated to developing innovative approaches to prevent retinal degeneration and restore vision in patients with severe vision impairment or blindness.
Afyren is a sustainable chemistry company based in Saint-Beauzire, France, focused on the valorization of non-food biomass to develop environmentally friendly alternatives to petroleum-based products. Founded in 2012, the company employs innovative biotechnological processes using natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. Its services extend to microbiology and bioprocess engineering, supporting various sectors including pharmaceuticals, cosmetics, green chemistry, and biopolymers. Afyren's approach aligns with the principles of a circular, low-carbon economy, emphasizing the importance of waste reduction and sustainable resource utilization.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
Enthera S.r.l. is a biotechnology company based in Milan, Italy, founded in 2016. The company focuses on developing innovative therapeutic approaches for diabetes and related gastrointestinal complications, particularly enteropathy, along with other intestinal disorders that share similar biological pathways. Enthera operates a monoclonal antibody discovery platform to create first-in-class biologics aimed at addressing these underserved conditions. The company was established as a subsidiary of BiovelocITA S.r.l. and was founded in collaboration with scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio. The name "Enthera" is derived from a combination of the terms "entero," referring to the intestine, and "therapy," reflecting its commitment to developing targeted treatments.
EryDel S.p.A. engages in the production and commercialization of drug delivery based on the use of autologous erythrocytes. The company provides medical devices which includes red cell loader, and erykit. The company was founded in 2007 and is based in Urbino, Italy.
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.
Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. The company currently works on four development programs: germination, flowering, growth, and weed control.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
Zyl is a mobile application designed to help users gather and share memories with friends and family. Launched in 2015 and based in Saint-Maur-des-Fossés, France, Zyl enables users to discover meaningful moments from their photo libraries and share these memories through events created within the app. Users can invite friends to participate in these events, view a shared timeline, and synchronize photos related to those moments. The app addresses the common dilemma of photo sharing, where only a small fraction of memories are shared due to concerns about privacy and social validation. By focusing on fostering genuine connections, Zyl provides a platform for users to relive and share their experiences, promoting interaction and engagement with loved ones. The company, formerly known as Comet, rebranded to Zyl in November 2017.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
MD Start SA offers fund placement services to medical device start-up corporations. It has partnerships with Medtronic, Sofinnova Partners, Sorin Group, Versant Ventures, Contract Medical International, and Corscience GmbH & Co. KG. The company, formerly known as Medical Device Accelerator, was founded in 2009 and is based in Lausanne, Switzerland.
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
MedDay is an innovative biopharmaceutical company specializing in the development of therapies for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company aims to create disease-modifying treatments that provide solutions for patients, caregivers, and the healthcare community, addressing significant unmet medical needs. MedDay's focus is on investigating brain metabolism to develop neuroprotective and neurorepair therapies, with promising clinical trial outcomes guiding their research efforts. By exploring disrupted metabolic pathways in the central nervous system, MedDay seeks to enhance future treatment options for individuals suffering from nervous system disorders.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from the waste streams of the food processing industry. The company has developed Curran, a material created from nano-cellulose fibers extracted from root vegetables. CelluComp offers Curran in both paste/slurry and powder forms, catering to a wide range of applications including paints, coatings, paper, food products, personal care items, home care products, cosmetics, concrete, drilling fluids, and composites. The company distributes its products through various partners across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp emphasizes the potential of sustainable materials produced from non-hydrocarbon feedstocks.
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
Twenga is a company that specializes in traffic acquisition solutions for online advertising marketplaces, focusing on enhancing advertising performance and automating investment strategies. Founded in September 2006 by Bastien Duclaux and Cedric Anes, Twenga operates from its headquarters in London, United Kingdom, and employs over 120 professionals across France, Germany, and England. The company serves more than 4,000 clients in 15 countries, providing services that include shopping search engine capabilities, online advertising, ecommerce support, retargeting, and product recommendations.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from the waste streams of the food processing industry. The company has developed Curran, a material created from nano-cellulose fibers extracted from root vegetables. CelluComp offers Curran in both paste/slurry and powder forms, catering to a wide range of applications including paints, coatings, paper, food products, personal care items, home care products, cosmetics, concrete, drilling fluids, and composites. The company distributes its products through various partners across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp emphasizes the potential of sustainable materials produced from non-hydrocarbon feedstocks.
Pixium Vision is a bioelectronics company based in Paris, France, focused on developing retinal implant systems to restore sight for individuals blinded by retinal degenerative diseases. The company is known for its PRIMA System, a bionic vision solution designed to treat blindness caused by the degeneration of photoreceptor cells in the retina. Pixium's initial device, the IRIS1, utilizes an epi-retinal implant and is undergoing clinical trials aimed at obtaining regulatory approval. A second-generation device, IRIS2, is in development, promising enhanced visual acuity through advanced technologies. Additionally, the company is working on IRIS3, a sub-retinal implant that aims to significantly improve vision compared to its predecessors. Established in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with several prestigious institutions, including Stanford University and Moorfields Eye Hospital, and is supported by prominent European venture capital firms.
MedDay is an innovative biopharmaceutical company specializing in the development of therapies for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company aims to create disease-modifying treatments that provide solutions for patients, caregivers, and the healthcare community, addressing significant unmet medical needs. MedDay's focus is on investigating brain metabolism to develop neuroprotective and neurorepair therapies, with promising clinical trial outcomes guiding their research efforts. By exploring disrupted metabolic pathways in the central nervous system, MedDay seeks to enhance future treatment options for individuals suffering from nervous system disorders.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on the research and development of epicutaneous immunotherapy products aimed at treating food allergies. The company’s lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children, adolescents, and adults. Additionally, DBV is developing Viaskin Milk, which is in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen’s egg allergy. The company is also working on a booster vaccine for Bordetella pertussis, along with earlier-stage research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company is headquartered in Montrouge, France.
Provide a web application filtering, authentication and intrustion prevention systems.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
QuesCom S.A. designs and manufactures Internet telecommunication systems. The company provides business communication management portal, GSM gateway, SIM servers, and mobile call servers. It partners with Aastra, Alcatel, Avaya Inc. & Cisco. QuesCom S.A. was founded in 1999 and is headquartered in Sophia Antipolis, France.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
Sensitive Object SA develops electronic products for the touch screen, consumer electronics and computing, outdoor interactive, white good, access control, home automation, health care, industrial control, and interactive digital advertising applications. Its products include touch screens, peripherals, and control panels. Sensitive Object SA was founded in 2003 and is based in Boulogne Billancourt, France. It has operations in Paris, France and Singapore, Singapore.
EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.
blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
Neosens SA engages in the design and development of sensor solutions and technologies to monitor and control water and industrial liquids. It offers sensors that monitor the presence of dissolved oxygen in liquid environments; and fouling systems for continuous fouling monitoring in liquid environments. The company’s solutions are used in various water and environmental applications, including cooling systems, heat exchangers, potable water, ultra-pure waters, and industrial boilers, as well as in food and beverage, pharmaceutical, pulp and paper, oil, gas, and petrochemical industries. The company was founded in 2001 and is based in Labege, France.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on the research and development of epicutaneous immunotherapy products aimed at treating food allergies. The company’s lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children, adolescents, and adults. Additionally, DBV is developing Viaskin Milk, which is in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen’s egg allergy. The company is also working on a booster vaccine for Bordetella pertussis, along with earlier-stage research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company is headquartered in Montrouge, France.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in network intelligence technology, particularly through embedded deep packet inspection (DPI) solutions. The company offers a range of products designed to classify and analyze IP traffic, including ixEngine, a comprehensive software development kit that features a decoding engine, protocol libraries, and real-time traffic classification tools. Their solutions support various applications such as network security, lawful interception, and regulatory compliance. Qosmos also provides professional services, including design and deployment support, as well as probe development services for telecom and enterprise developers. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates as a subsidiary of Enea AB, focusing on transforming networks into information sources that enhance application and service awareness.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
STENTYS S.A., a medical technology company, develops solutions for treating patients with acute myocardial infarction and other coronary disease in Europe, the Middle East, Latin and South America, and South East Asia. Its product portfolio consists of Xposition S, a sirolimus-eluting self-apposing coronary stent system; Serpentis, a sirolimus eluting stent with a bioabsorbable polymer; MiStent SES, a sirolimus eluting absorbable polymer coronary stent system; and STENTYS AC, an aspiration catheter. The company serves interventional cardiologists. STENTYS S.A. was founded in 2006 and is based in Paris, France.
Neosens SA engages in the design and development of sensor solutions and technologies to monitor and control water and industrial liquids. It offers sensors that monitor the presence of dissolved oxygen in liquid environments; and fouling systems for continuous fouling monitoring in liquid environments. The company’s solutions are used in various water and environmental applications, including cooling systems, heat exchangers, potable water, ultra-pure waters, and industrial boilers, as well as in food and beverage, pharmaceutical, pulp and paper, oil, gas, and petrochemical industries. The company was founded in 2001 and is based in Labege, France.
Inside Secure, founded in 1995 and based in Aix en Provence, France, specializes in open-standard contactless payment and near field communication (NFC) semiconductors and software. The company develops a range of products including contactless reader interface chips, NFC interface circuits, contactless payment platforms, memory chips, and desktop readers. These products are utilized in various applications such as payment, transit, identity verification, and access control across smart cards, key fobs, mobile devices, and POS systems. Inside Secure also provides professional services for integration and adoption, encompassing application development and system integration. The company's clientele includes payment card and mobile phone manufacturers, systems integrators, and financial institutions, with additional offices in Shanghai, Singapore, Warsaw, Seoul, San Francisco, and Boston.
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.
Purple Labs SA specializes in developing mobile Linux software solutions tailored for real-time operating systems (RTOS) and Linux-based mobile devices. The company offers a comprehensive software suite known as The Mobile Linux Platform, which assists in the creation of mobile feature phones. Additionally, it provides an Application suite designed for 3G feature phones, including various browser and messaging applications for both manufacturers and end-users. Purple Labs also produces the Purple Magic, a 3G Linux feature phone that supports video telephony, music playback, high-speed internet browsing, and video streaming. Beyond its software offerings, the company delivers services such as application integration, customization of Linux support packages, hardware design assistance, and product industrialization. Founded in 2001 and headquartered in Le Bourget du Lac, France, Purple Labs maintains offices in multiple countries, including the United States and China. As of 2009, Purple Labs operates as a subsidiary of Myriad Group AG.
Inside Secure, founded in 1995 and based in Aix en Provence, France, specializes in open-standard contactless payment and near field communication (NFC) semiconductors and software. The company develops a range of products including contactless reader interface chips, NFC interface circuits, contactless payment platforms, memory chips, and desktop readers. These products are utilized in various applications such as payment, transit, identity verification, and access control across smart cards, key fobs, mobile devices, and POS systems. Inside Secure also provides professional services for integration and adoption, encompassing application development and system integration. The company's clientele includes payment card and mobile phone manufacturers, systems integrators, and financial institutions, with additional offices in Shanghai, Singapore, Warsaw, Seoul, San Francisco, and Boston.
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
STENTYS S.A., a medical technology company, develops solutions for treating patients with acute myocardial infarction and other coronary disease in Europe, the Middle East, Latin and South America, and South East Asia. Its product portfolio consists of Xposition S, a sirolimus-eluting self-apposing coronary stent system; Serpentis, a sirolimus eluting stent with a bioabsorbable polymer; MiStent SES, a sirolimus eluting absorbable polymer coronary stent system; and STENTYS AC, an aspiration catheter. The company serves interventional cardiologists. STENTYS S.A. was founded in 2006 and is based in Paris, France.
blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers.
We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers.
Oxxius is headquartered in western France and located among a major optics and photonics cluster.
Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared.
Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.
Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in network intelligence technology, particularly through embedded deep packet inspection (DPI) solutions. The company offers a range of products designed to classify and analyze IP traffic, including ixEngine, a comprehensive software development kit that features a decoding engine, protocol libraries, and real-time traffic classification tools. Their solutions support various applications such as network security, lawful interception, and regulatory compliance. Qosmos also provides professional services, including design and deployment support, as well as probe development services for telecom and enterprise developers. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates as a subsidiary of Enea AB, focusing on transforming networks into information sources that enhance application and service awareness.
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.
Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on the research and development of epicutaneous immunotherapy products aimed at treating food allergies. The company’s lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children, adolescents, and adults. Additionally, DBV is developing Viaskin Milk, which is in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen’s egg allergy. The company is also working on a booster vaccine for Bordetella pertussis, along with earlier-stage research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company is headquartered in Montrouge, France.
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.
Sefas Innovation was founded in 1991 and has been providing collaborative document composition & production software to Fortune 500 companies for over 15 years. Sefas’ corporate headquarters is in Paris, France, which, along with its UK and US offices, supports over 80 Sefas staff worldwide. Sefas’ Open Print software suite is used by financial services, banking, insurance, utilities, telecoms and public sector organisations for the design, composition and production of B2C documents. These are often complex documents with multiple sources of data; Open Print is unique in its ability to integrate the data from these multiple sources to provide personalized and relevant communications. Increasingly Open Print is being used to redesign mission critical documents so that they can also communicate the latest marketing campaigns and so generate new revenue. The Sefas UK office is based in Bristol and was first opened in 1999. Sefas’ UK clients include Nationwide, EDS Credit Services (Abbey National), HBOS, Inland Revenue, Department of Work & Pensions, Royal & Sun Alliance, RR Donnelley, Bank of Tokyo, DST International and British Telecom who have been using Open Print since (2000).